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In the present study, we analyzed the cell cycle distribution of bone marrow (BM) cells in 120 untreated multiple myeloma patients using a DNA/CD38 double-staining technique at flow cytometry in which plasma cells (PCs) can be clearly discriminated from residual BM cells based on their CD38 expression. This approach allows us t o determine the proliferative activity of both PCs and residual normal BM cells. The percentage of S-phase cells in the myelomatous population was found t o be significantly lower than that of the residual normal BM cells ( P < .001). Regarding the proliferative activity of myelomatous cells, patients with a high number of S-phase PCs (>3%) showed a significantly (P < .05) increased incidence of anemia and hypercalcemia;
higher values of P,-microglobulin (&M), urea, and creatinine; and higher numbers of peripheral blood natural killer cells, as well as a poor prognosis as assessed both by response duration and overall survival. With respect t o the NCREASED USE of intensive therapeutic approaches for the treatment of patients with multiple myeloma (MM) makes the identification of different prognostic subgroups very important. This distinction would allow better patient counseling and an improved evaluation of clinical trials. Among the different prognostic factors identified in MM patients, one of the most important is the proliferative activity of plasma cells (PCs) -the proportion of PCs that synthesize This has generally been assessed by the labeling index (LI) obtained after incubation of cells in the presence of tritiated thymidine"' or brom~deoxiuridine."~ These techniques are relatively complex and time-consuming and, in some cases, include the use of radioactive isotopes. Because of this, they have not been extensively used and are still restricted to research laboratories, despite the proven clinical value of the L1 for both the identification of patient subgroups with different and for the differential diagnosis between MM and monoclonal gammopathies of undetermined ~ignificance.~.'
In recent years, flow cytometry has provided new insights into the biology of neoplastic cells, including cell-cycle analysis. Although several studies have analyzed the cell-cycle distribution in different hematologic malignancies, quite variable and discrepant results have been obtained; at least residual BM normal fraction, a low proliferative activity was significantly ( P < .05) associated with the presence of anemia and neutropenia together with increased numbers of BM PCs, a higher incidence of Ben-Jones myelomas, and DNA diploidy. Multivariate analysis showed that the number of S-phase PCs was the most important independent prognostic factor, allowing us t o discriminate two subgroups of patients with different prognoses, even within the same clinical stage. Moreover, the S-phase PCs, together with &M, age, and performance status, represent the best combination of disease characteristics for stratifying patients according t o prognosis and allow the establishment of a simple and powerful staging system for multiple myeloma patients. In addition, this classification can be used for planning treatment in patients who are candidates for transplantation. 0 1995 by The American Society of Hematology.
in part, this is probably related to technical artifacts as was recently been pointed out by the DNA Consensus Conference for the standardization of studies on cell DNA content.""' Accordingly, it has been indicated that the influence of several artifacts in the flow cytometric assessment of Sphase cells in bone marrow (BM) of MM patients should be resolved in advance. Of the factors that may influence the results, the most relevant fact is that, in MM BM samples, PCs coexist with residual normal cells that are usually proliferating. For this reason, some have used simultaneous staining of DNA and cytoplasmic Ig to discriminate PCs. However, although being of help for the identification of aneuploid DNA peaks, the separation between PCs and normal residual cells that this technique provides is not sufficient for cell-cycle analysis purposes.
Immunophenotypical studies by flow cytometry have shown that PCs display a singularly high reactivity for the CD38 antigen, which allows a clear distinction between PCs and the other BM cell population^.""^ Taking advantage of this strong reactivity for the CD38 antigen detected in PCs, we have used a double DNAKD38 staining technique in which PCs can be clearly discriminated from residual BM cells based on their CD38 expression. Thus, the cell-cycle distribution of MM PCs can be calculated separately from that of the residual cells.I8 In the present study, we have evaluated the proliferative activity of both myelomatous PCS and residual normal BM cells in 120 untreated myeloma patients, using an easy-to-perform, standardized and reproducible method'x," for measuring the S-phase of both cell populations. The most important independent prognostic factor was the proportion of S-phase PCs, which together with B,-microglobulin @,M), age, and performance status allowed the establishment of a simple and powerful staging system for MM patients. were treated according to the protocol of the Spanish cooperative group PETHEMA" which includes either melphalan and prednisone (43% of cases) or alternating cycles of VCMPNBAP (57% of cases). No significant differences were observed regarding the treatment used.'' The median survival for the whole series was 37 months.
MATERIAL AND METHODS

Patients.
In each patient, the most relevant clinical and laboratory disease characteristics documented at diagnosis were evaluated for their prognostic significance. These included clinical features (age, sex, performance status according to the Eastern Cooperative Oncology Group (ECOG) scale, bone pain, loss of weight, the presence of hepato-splenomegaly and the existence of plasmacytomas), hematologic parameters (hemoglobin, white blood cell [WBC] and platelet counts, and erythrocyte sedimentation rate [ESR]), serum biochemical data (creatinine, urea, calcium, lactic dehydrogenase [LDH], and PZM levels), electrophoretic characteristics (total proteins, albumin, type of monoclonal (M) component and the presence of urine Ig light chains), percentage of BM plasma cells (PCs), and the presence or absence of bone lesions. In addition, patients were grouped into clinical stages according to Dune and Salmon's'' criteria.
The median age of the cohort studied was 69 years (range, 38 to 91). with 62 males and 58 females. According to their clinical stages, patients were distributed as follows: LA, 6%; IIA, 24%; IIB, 2%; IIIA, 52%; IIIB, 16%. A serum creatinine 2 2 mg/dL was present in 18% of patients. Serum calcium was greater than 11 mg/dL in 25% of patients.
A monoclonal serum component was found in 86% of patients: IgC, 55%; IgA, 30%; IgD, 1 %. The remaining 13% had Bence Jones myeloma. In 1% of the patients, no monoclonal serum protein or monoclonal urine protein was identified. The serum monoclonal light chain was K in 63% and X in 37%. Urine immunoelectrophoresis was performed in all patients. In 45% of the cases, a urine monoclonal light chain was detected.
Criteria fur respunse. An objective response (OR) was defined as ( l ) a reduction of 50% or more of the M component, (2) improvement in performance status by at least two grades, and (3) a decrease of greater than 50% in the measured cross-sectional area of plasmacytomas. Furthermore, the size and number of lytic bone lesions should not have increased, and correction of hypercalcemia (< 1 1 .O mgldL), anemia (>9 mg/dL), and hypoalbuminemia (>3.5g/dL) should also have occurred. Those patients who fulfilled all the above criteria, but who had less than 50% reduction of M component were considered to have had a partial response (PR). When the criteria for an OR or PR were not fulfilled, the case was considered a treatment failure." Patients who died before completion of the proposed treatment were considered early deaths. Within the group of patients with objective response, those who had no detectable M component and less than 5% of BM PCs were considered complete responses. Finally, relapse was defined as an increase of greater than 50% from the lowest level of serum M component achieved with the initial therapy, an increase in size or number of lytic bone lesions, and the development of extraosseus plasmacytomas, anemia, and/or hypercalcemia. Overall survival (OS) was considered from the moment of diagnosis to the moment of death, and response duration (D), from the moment at which response was obtained until the relapse.
~z M levels. Serum PzM levels were measured by a radioimmunoassay method (Immunotech SA, Marseille, France). The upper limit in 20 sex-and age-matched healthy individuals was 1.6 pg/ mL. In the present series of MM patients, the mean value was 5.8 2 
pglmL (median value, 4.1 pg/mL).
DNAploidy studies. To analyze the presence or absence of DNA aneuploidy, the technique of Vindelov et al'' was used, Measurements were performed on a FACScan flow cytometer (Becton Dickinson, San JosC, CA) for at least 10, OOO eventdsample, using the CellFit software program (Becton Dickinson). In the present series, 56% of patients had DNA hyperdiploidy, and 2% were hypodiploid.
Cell cycle analysis. For cell-cycle analysis a double-staining procedure using CD38 and propidium iodide (PI) was used. Briefly, between 100 and 200 p L of diluted whole BM containing 0.5 to 1 X lo6 WBCL was placed in the bottom of the tube. Cells were then incubated for 15 minutes at room temperature with 10 pL of the GR7A4 (CD38) monoclonal antibody (MoAb), washed once (5 minutes, 1,900 rpm) in phosphate-buffered saline (PBS) and incubated for another 15 minutes in the dark (room temperature) with an antimouse Igs MoAb (F[ab']' fragments) (Dakopatts, Copenhagen, Denmark). Afterwards, 2 mL of ammonium chloride was added and cells incubated in the dark for another 10 minutes (room temperature). Cells were then washed once in 1 mL of sodium citrate buffer and resuspended in 200 pL of sodium citrate buffer. Afterwards, 1.5 mL of solution B, containing RNAse was added and cells incubated for another 10 minutes period in the dark at room temperature. Finally, 1.5 mL of solution C, containing PI, was added and another incubation for at least 10 minutes in the dark (room temperature) was performed. Measurements were performed within 30 minutes after the technique was finished on a FACScan flow cytometer using the CellFit software, and counting at least 10,ooO cellslsample. The percentage of both CD38 strong-positive cells and the remaining cell populations were calculated after excluding cell doublets on a FL2-AreaFL2-Width dot plot using the PAINT-A-GATE-PLUS software (Becton Dickinson). The proportion of cells in the different cell-cycle phases was calculated using the RFIT mathematical model included in the CellFit software after excluding cell doublets and gating on both the CD38 strong-positive and remaining cells, as previously reported." To identify the cell cycle of PCs, we selected the gate for CD38 strongly positive cells, where there are only PCs, using the same software. As internal controls and in order to confirm the type of cells included in these gates, we have performed sorting experiments simultaneously on both CD38 strong-positive cells and the remaining cells in four patients using a FACStar flow cytometer. The sorting was based on the cell DNA content and reactivity for CD38. Ninety-seven percent ? 2% of the cells on the CD38"' sorted fraction were plasma cells, as assessed by both morphologic and immunologic criteria (cIgk+ or cIgl' cells); by contrast, the percentage of plasma cells in the other cell sorted fraction was lower than 1% in all four cases analyzed (0.6% 2 0.4%)." Moreover, in aneuploid cases, only the strongly CD38-positive cells showed an abnormal DNA content. An additional theoretical problem with this technique could be the existence of MM cases lacking a strong CD38 positivity; however, in our series, only two cases displayed a weak CD38 expression.
In some cases with few PCs, the mathematical model could not analyze the cell cycle. In most of these cases, this problem could be overcome by acquiring a larger number of cells or through an additional acquisition using a live gate for the CD38 strong-positive cells. Nevertheless, 2% of cases could not be analyzed because their histograms did not adjust to the mathematical model. Overall, the percentage of cases successfully analyzed was 91.7% (120/131).
Statistical methods. To estimate the significances of the differences between means, Student's t-test was used (SPSS, Chicago, IL). The chi-square test (SPSS) was used for dichotomic variables.
The different clinical and biologic characteristics were considered individually for their relationship with the probability of achieving a favorable response to treatment by univariate tests (Student's ttest, chi-square, correlations and nonparametric tests, SPSS). Subsequently, a multivariate analysis-stepwise regression-(regression, SPSS)'4 was performed to examine the simultaneous effect of the different variables on the probability of achieving a favorable response.
The same characteristics were again considered for analysis with respect to their individual and simultaneous effects on response duration (RD) and overall survival (0S)"univariate and multivariate analysis, BMDP 1L and 2L, respectively.'' RD and OS curves were plotted according to the method of Kaplan and Meier, and compared using the Mantel-Cox, Peto-Prentice, and Breslow tests. Variables considered for possible inclusion in the regression analysis were those displaying a significant association with survival in the univariate analysis ( P < .OS) or for which prior studies had suggested a possible prognostic value. The stepwise regression method was discontinued when the P value for entering an additional factor was above .OS. The model was tested both by including the variables in a continuous fashion (continuous model) and by grouping them into categories (dichotomous model).
RESULTS
Cell-cycle distribution.
According to the intensity of CD38 expression, myelomatous plasma cells (CD38 strong positive) were clearly discriminated from normal residual BM cells, which allowed us to analyze separately the cellcycle distribution of both cell fractions (Fig 1) . In the whole series of 120 newly diagnosed untreated MM patients, it was observed that the percentage of S-phase cells in the myelomatous fraction was significantly lower than that of the residual normal BM cell population (3.6% 2 3.1% and 8.0% 2 6.3%, P < ,001). The number of cells in the G2/ M-phase was similar in both fractions, while the proportion of GO/Gl-phase cells was higher within the myelomatous PC population (Table 1) .
Proliferative activity of BM plasma cells. Myeloma patients were also divided into two groups using the median value of the present series (3% of S-phase PCs) as the cutoff point according to the proliferative activity of the BM PCs. The clinical, hematologic and biochemical characteristics of both groups of patients are shown in Table 2 . Patients with more than 3% of S-phase PCs showed a significantly higher incidence of anemia ( P = .04) and hypercalcemia ( P = .008); increased values of P2M ( P = .001), urea ( P = .001), and creatinine ( P = .0001) together with higher numbers of PB natural killer cells (0.01), and a poor prognosis Fig 2) as assessed both by the response to chemotherapy ( P = .02) and survival ( P < .0001) ( Table 2 ). The median survival of these patients was only 19 months compared with 56 months for the patients displaying less than 3% S-phase PCs. In addition, our results also show that this cut-off value of S-phase BM PCs allows the discrimination of two significantly different prognostic groups of patients even within individual clinical stages (Fig 2, B and C ).
S-phase was able to identify high-risk patients that would have not been recognized according to other criteria. Thus, within the group of patients with high S-phase PCs (>3%) 46% were under 69 years of age, 26% were in clinical stage I or 11, 42% had few bone lesions (grade 0 or l ) , 27% had levels of hemoglobin (Hb) > 10.5 g/dL, 50% had normal albumin serum levels (>3.5 g/dL), 62% had normal renal function (creatinine < 2.0), 54% did not display hypercalcemia (calcium < 10.5 mg/mL) and 48% had low levels of P2M (<6 pg/mL).
Prolijercltive activity qf residual BM cells. When the patients were grouped according to the number of residual normal BM cells in the S-phase (Table 3) , it was observed that cases displaying a low proliferative activity (<4.5% Sphase cells) showed a significantly higher incidence of severe anemia ( P = .03) and neutropenia ( P = .03) together with increased numbers of BM PCs ( P = ,003). In addition, both Bence Jones ( P = ,0002) and diploid ( P = .009) MMs were more frequent among this group of patients. Interestingly, in six patients, circulating PCs were observed morphologically and five of these were in the group of patients displaying low numbers of S-phase cells ( P = .01). From the prognostic point of view, patients in which the normal residual BM cells displayed a low proliferative rate had a slightly shorter survival (median survival of 22 v 36 months), although the differences did not reach statistical significance.
Prognostic ,factors and clinical system. Regarding response to chemotherapy, univariate analysis showed that the individual disease characteristics associated with a favorable response (objective and partial remission) were low proliferative activity (<3%) of BM plasma cells ( P = .02), age less than 69 years ( P = .02), ECOG less than 3 ( P = .002), &M less than 6 pg/mL ( P = .002), Hb greater than 10.5 g/dL ( P = .009), creatinine greater than 2 mg/mL ( P = .0l), low serum urea levels ( P = .03), calcium less than 11 mg/mL ( P = .02), and early clinical stages (stage I and 11) ( P = .03). However, the only independent prognostic factors predicting the response to chemotherapy were found to be P2M serum levels and the performance status ( P < .05). Regarding response duration, the only two variables significantly associated with a shorter response duration of independent value were the presence of more than 3% of S-phase PCs (P = .002) (Fig 3) and the presence of plasmacytomas at diagnosis (P = .03). Regarding the population with high Sphase, only 44% of patients achieved an OR, and 12% had a minor response. In the remaining patients, there was no response. Interestingly, 21% of patients with OR relapsed within the following 4 months. The question of whether the proliferative activity of BM PCs has independent prognostic influence on survival, because of its correlation with other prognostic parameters, was investigated using the Cox regression analysis. Multivariate analysis (Table 4 ) showed that the percentage of S-phase PCs was the best single parameter for predicting survival in MM patients; this parameter, together with the P2M serum levels, performance status and age were the best combination of disease characteristics for predicting survival in MM. In 10 of 60 patients (17%) with high S-phase PCs (>3%), this was the only adverse prognostic feature because all the other independent prognostic factors @,M, age, and performance status) were favorable. When only patients less than 65 years old were included in the multivariate analysis, the only disease parameters to emerge as significant prediction were the percentage of S-phase cells (P < .001) and P2M serum levels
According to the hazard rate predicted by the regression model (Fig 4) patients were divided into three risk groups using cut-off points of 6 and 8.5; a high-risk group including 21% of the patients, an intermediate-risk group including 53%, and a low-risk group including 26% were found. The median survivals of these three groups were 9 and 36 months
and not yet reached, respectively ( P < .0001). Interestingly, none of the 31 patients included in the low-risk group have died so far. All of these patients had symptomatic MM, 54% of them were in clinical stage I11 and extensive bone lesions (grade 2 or 3) were present in 46% of these cases. Their median age was 64. Anemia (<10.5 g/dL) was observed in SO%, albumin less than 3.5 g/dL in 24% and serum P,M level between 4 and 6 mg/dL were present in 24%. To simplify the classification of MM patients into risk groups, an alternative model was developed according to the scoring indices shown in Table 5 . The survival curves of patients with low risk (score 0), intermediate risk (score 1, 2 or 3) and high risk (score 4 or 5 ) were similar to the ones described above, and the differences between them were also highly significant (P < .0001) ( Fig 5) .
DISCUSSION
Accurate prognostic evaluation is mandatory for the selection of optimal therapeutic strategies in hematologic malignancies, especially when a decision on treatments with increased concomitant morbidity and mortality, such as use only. Abbreviation: NS, not significant (P > .05).
.01 transplantation, must be made. Moreover, a good staging system would allow the identification of patients at risk of early death who may benefit from new experimental treatments. The plasma cell labeling index (PCLI), assessed as the number of plasma cells that incorporate thymidine analogues, has been shown to represent an important prognostic factor in MM, potentially useful for predicting progression of the tumor clone.2,3,6,8.9 However, its determination is rela- not an appropriate way of assessing plasma cell proliferation since normal residual cells are also proliferating in the BM of myeloma patients. The CD38/propidium iodide doublestaining technique used in the present study" allows the simultaneous evaluation of the myelomatous population specifically identified as being strongly CD38 positive and the residual normal BM cell populations. Our data show that myelomatous PCs proliferate relatively slowly as compared with residual BM cells.
So far, very little attention has been paid to the residual normal BM cell populations in MM and, to the best of our knowledge, this is the first study in which their proliferative activity has been correlated with the most relevant clinical disease characteristics. Our results show that both Hb levels and the number of PB granulocytes in MM patients are related to the proliferative activity of residual BM cells as an index of their regenerative activity.
Regarding the proliferative activity of myelomatous PCs we observed that the number of S-phase PCs correlated with several prognostic factors, such as the level of Hb, calcium, creatinine, and P2M. Moreover, using an S-phase cut-off value of 3%, it was possible to discriminate two subgroups of patients with significant different prognoses, even within individual clinical stages. In a similar way to what has been reported for the PCL16-* and other chronic lymphoprolifera- tive disorders,29 multivariate analysis showed that the number of S-phase PCs was the most important independent prognostic factor and that, together with P2M, age, and the performance status, it represented the best combination of disease characteristics for stratifying patients according to prognosis, thus providing a useful basis for risk-directed therapy. Accordingly, it should be emphasized that together with a group of patients at risk of early death (22% of our cases), the model described here identified another similar group of patients, all of which are alive and are characterized by a low percentage of S-phase PCs, low serum 0,M levels, and age less than 69 years. According to classic criteria, such as the clinical stage (54% of them were in stage 111) or anemia (50% had Hb < 10.5 g/dL), these patients would not have been recognized as low-risk cases and, therefore, might have been subjected to unnecessary, perhaps lifethreatening, aggressive treatments. A similar observation has been recently reported by Greipp et aI9 using a stratification model based on PCLI and P2M levels; in this study, eight of nine patients under the age of 65 with low PCLI and P2M were alive after more than 5.5 years of follow up.
The percentage of S-phase PCs apparently does not play a crucial role in predicting response to treatment because it was not selected in the multivariate analysis for response. Other studies based on the PCLI have reported similar re-sults2; this may be because response to treatment seems mainly to depend on tumor cell mass' and the presence of mechanisms of drug resi~tance.~'.~' By contrast, we observed that response duration was related to the proliferative activity of the PCs because the number of S-phase cells was the most important prognostic factor for predicting relapse. This The sum of scores gives three stages: stage I, score 0; stage II: score l to 3; stage 111, score 4 to 5. Table 5 : S-phase PCs 23% (2). ~3 % (0); &M 2 6 pg/mL (l), <6 pg/mL (0); ECOG 2 3 (l), <3 (0); age 269 yrs (l), C69 yrs (0). The sum of these values gives the score risk.
observation suggests that the proliferative activity of the residual cells resistant to chemotherapy is a major factor for disease progression.* In summary, our results show that the assessment of the number of S-phase PCs at flow cytometry, combining CD38 and PI staining, is the most significant independent predictor of survival in MM. Moreover, the classification system proposed here includes the three basic features that define the prognosis in most tumor models: (1) the malignant cells growth (assessed by plasma cells' S-phase), (2) the tumor load (assessed by &M), and (3) the patients' ability to tolerate the malignancy and the treatment (age and performance status). Finally, this classification could also be used for planning treatment in patients who are younger than 65 years old, have a good performance status, and who are candidates for transplantation.
